Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.

doi:10.1038/bjc.2017.294

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.

British journal of cancer - 24 Oct 2017

Gollins Simon, West Nick, Sebag-Montefiore David, Myint Arthur Sun, Saunders Mark, Susnerwala Shabbir, Quirke Phil, Essapen Sharadah, Samuel Leslie, Sizer Bruce, Worlding Jane, Southward Katie, Hemmings Gemma, Tinkler-Hundal Emma, Taylor Morag, Bottomley Daniel, Chambers Philip, Lawrie Emma, Lopes Andre, Beare Sandy

Abstract excerpt

BACKGROUND: The influence of EGFR pathway mutations on cetuximab-containing rectal cancer preoperative chemoradiation (CRT) is uncertain. METHODS: In a prospective phase II trial (EXCITE), patients with magnetic resonance imaging (MRI)-defined non-metastatic rectal adenocarinoma threatening/involving the surgical resection plane received pelvic radiotherapy with concurrent capecitabine, irinotecan and cetuximab....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Cetuximab

Share to Chemoradiotherapy

Share to Class I Phosphatidylinositol 3-Kinases

Share to Combined Modality Therapy

Share to Irinotecan

Share to Rectal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28859058
DOI: 10.1038/bjc.2017.294
PMCID: PMC5672930

Genes

KRAS
BRAF
EGFR
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.PMID 28859058Read ↗

RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.Semantic proximity Read ↗

KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.Semantic proximity Read ↗

Response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT pathway dysregulation and high tumour mutational burdenSemantic proximity Read ↗

Prognostic Impact of Ras Mutation on Surgical Strategy in Rectal Cancer Patients Undergoing Neoadjuvant Treatment.Semantic proximity Read ↗

KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.Semantic proximity Read ↗

MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.Semantic proximity Read ↗

Influence of KRAS mutation subtypes on response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: meta-analysis.Semantic proximity Read ↗

Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.Semantic proximity Read ↗

KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.Semantic proximity Read ↗

Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.Semantic proximity Read ↗

Genomic-adjusted radiation dose and outcomes in radiotherapy-treated locally advanced rectal cancer: a pooled multicohort analysis including the TIMING, OPRA, and CAO/ARO/AIO-94 prospective trialsSemantic proximity Read ↗

Association Between RAS/BRAF Mutations and Complete Response Following Total Neoadjuvant Therapy in Patients with Rectal Cancer: A Prospective Multicentered Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.